By Ashley Schwalje, Senior GTM Manager, Clinical R&D Strategy, Informa Pharma Intelligence and Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence
Study feasibility is a fundamental contributor to the overall success of a clinical development program. However, selecting the right countries, sites and investigators and starting up as quickly as possible remains a challenge, leading to greatly variable performance and inaccurate predictions for important trial milestones. Current approaches can best be described as a blend of art and science, requiring time-intensive data analysis, deep contextual understanding, and a healthy slice of good fortune to meet enrollment targets. In this article, the second of a two-part series, Informa Pharma Intelligence introduces a first-of-its-kind artificial intelligence (AI) solution for this critical industry problem.